The U.S. Food and Drug Administration has approved Cytokinetics' oral drug to treat a rare heart condition, the company said ...

Aficamten shows cardiac benefits over blood pressure drug metoprolol Analysts see potential for aficamten to replace beta-blocker drugs for treating HCM Cytokinetics plans to submit data to regulators ...

Cytokinetics aims to compete with a Bristol Myers Squibb heart drug projected to become a blockbuster seller, and the company’s value proposition is that its drug candidate has a potential safety edge ...

“TY1 is the first exomer – a new class of drugs that address tissue damage in unexpected ways.” TY1 has the structure of existing RNA drugs, and works like its natural version – amplifying the ...

The clearance is the first in Cytokinetics’ lengthy history and pits its drug Myqorzo against Bristol Myers’ Camzyos, which ...

Treating blood pressure with antihypertensives like blood vessel relaxers (ARB drugs) can provide increased life expectancy ...

Cytokinetics Inc. won US approval for a drug to treat a deadly heart condition, posing a potential threat to sales of a similar Bristol Myers Squibb Co. treatment that’s expected to be a key growth ...

CHARLESTOWN, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular ...

Internal organ tissues often don’t heal after illness or injury and lose some function, such as the heart after a heart attack. UCLA cardiologists have identified a protein that interferes with ...